Song Jiayin, Jin Yu, Fan Shuoqing, Wei Yue, Dong Dong, Jia Li, Fan Shuxuan, Zhang Aimin, Zhou Wei, Jiang Wenna, Ren Li
Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin 300060, China.
Clinical medical college of Tianjin Medical University, Tianjin, China.
J Cancer. 2024 Aug 13;15(16):5218-5229. doi: 10.7150/jca.98337. eCollection 2024.
Few robust biomarkers are available for distant metastatic colorectal cancer (CRC) patients. Aberrant high expression of CDH3 has been reported in advanced CRC patients, but the value of CDH3 as a biomarker for the diagnosis and prognosis of distant metastatic CRC patients remains to be evaluated. In this study, we explored the serum levels of CDH3 in different stages of CRC patients and sought to determine whether serum CDH3 serves as an independent biomarker for distant metastatic CRC patients. We analyzed the serum CDH3 levels by ELISA in a cohort of CRCs (n=96) and normal controls (n=28). We compared the serum CDH3 levels between normal controls and different stages of CRCs. As a potential diagnostic marker of distant metastatic CRC, the specificity and sensitivity of serum CDH3 were evaluated. Multivariate analysis was also performed to determine whether serum CDH3 was an independent risk factor. Moreover, the changes of serum CDH3 levels were monitored and analyzed before and after palliative chemotherapy. Serum levels of CDH3, CA24-2, CA19-9, CA72-4, and CEA were significantly elevated in distant metastatic CRCs. CA24-2 (=0.24, =0.01), CA19-9 (=0.20, =0.03), CA72-4 (=0.64, <0.0001), and CEA (=0.31, =0.0012) all had a certain correlation with CDH3. After three cycles of palliative chemotherapy, levels of CDH3, CA24-2, CA19-9, CA72-4, and CEA of partial response CRCs were reduced to 38.8% (95% confidence interval [CI]: 30.95%-53.77%), 57.73% (95% CI: 2.085%-73.83%), 50.33% (95% CI: 9.935%-79.42%), 74.74% (95% CI: 25.21%-88.00%), and 59.16% (95% CI: 12.65%-83.56%) of baseline, respectively. The areas under the receiver operating characteristic curves of CDH3, CA24-2, CA19-9, CA72-4, and CEA with chemotherapy response were 0.900, 0.597, 0.635, 0.608, and 0.507, respectively. Serum CDH3 is an effective serum biomarker for the diagnosis of distant metastatic CRCs and monitoring response to palliative chemotherapy in distant metastatic CRCs.
对于远处转移性结直肠癌（CRC）患者而言，几乎没有可靠的生物标志物。已有报道称晚期CRC患者中CDH3呈异常高表达，但CDH3作为远处转移性CRC患者诊断和预后生物标志物的价值仍有待评估。在本研究中，我们探究了CRC患者不同阶段的血清CDH3水平，并试图确定血清CDH3是否可作为远处转移性CRC患者的独立生物标志物。我们通过酶联免疫吸附测定（ELISA）分析了一组CRC患者（n = 96）和正常对照者（n = 28）的血清CDH3水平。我们比较了正常对照者与不同阶段CRC患者的血清CDH3水平。作为远处转移性CRC的潜在诊断标志物，我们评估了血清CDH3的特异性和敏感性。还进行了多变量分析以确定血清CDH3是否为独立危险因素。此外，在姑息化疗前后监测并分析了血清CDH3水平的变化。远处转移性CRC患者的血清CDH3、CA24-2、CA19-9、CA72-4和癌胚抗原（CEA）水平显著升高。CA24-2（= 0.24，= 0.01）、CA19-9（= 0.20，= 0.03）、CA72-4（= 0.64，<0.0001）和CEA（= 0.31，= 0.0012）均与CDH3有一定相关性。经过三个周期的姑息化疗后，部分缓解的CRC患者的CDH3、CA24-2、CA19-9、CA72-4和CEA水平分别降至基线的38.8%（95%置信区间[CI]：30.95%-53.77%）、57.73%（95% CI：2.085%-73.83%）、50.33%（95% CI：9.935%-79.42%）、74.74%（95% CI：25.21%-88.00%）和59.16%（95% CI：12.65%-83.56%）。CDH3、CA24-2、CA19-9、CA72-4和CEA与化疗反应的受试者工作特征曲线下面积分别为0.900、0.597、0.635、0.608和0.507。血清CDH3是诊断远处转移性CRC以及监测远处转移性CRC姑息化疗反应的有效血清生物标志物。
